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Background Cigarette smoking is associated with lower body mass index (BMI),
and a commonly cited reason for unwillingness to quit smoking is
a concern about weight gain. Common variation in the CHRNA5-
CHRNA3-CHRNB4 gene region (chromosome 15q25) is robustly
associated with smoking quantity in smokers, but its association
with BMI is unknown. We hypothesized that genotype would ac-
curately reflect smoking exposure and that, if smoking were caus-
ally related to weight, it would be associated with BMI in smokers,
but not in never smokers.
Methods We stratified nine European study samples by smoking status and, in
each stratum, analysed the association between genotype of the 15q25
SNP, rs1051730, and BMI. We meta-analysed the results (n¼ 24 198)
and then tested for a genotype smoking status interaction.
Results There was no evidence of association between BMI and genotype in
the never smokers {difference per T-allele: 0.05 kg/m2 [95% confi-
dence interval (95% CI): 0.05 to 0.18]; P¼ 0.25}. However, in ever
smokers, each additional smoking-related T-allele was associated
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with a 0.23 kg/m2 (95% CI: 0.13–0.31) lower BMI (P¼ 8 106).
The effect size was larger in current [0.33 kg/m2 lower BMI per
T-allele (95% CI: 0.18–0.48); P¼ 6 105], than in former smokers
[0.16 kg/m2 (95% CI: 0.03–0.29); P¼ 0.01]. There was strong evi-
dence of genotype smoking interaction (P¼ 0.0001).
Conclusions Smoking status modifies the association between the 15q25 variant
and BMI, which strengthens evidence that smoking exposure is
causally associated with reduced BMI. Smoking cessation initiatives
might be more successful if they include support to maintain a
healthy BMI.
Keywords Smoking, BMI, SNP, genetic association, interaction
Introduction
Cigarette smoking is a major preventable cause of
death and disease.1 However, while the majority
of smokers report a willingness to quit, only a rela-
tively small proportion attempt to do so in any given
year.2 One reason commonly cited for being unwilling
to stop smoking is a concern about weight gain fol-
lowing cessation,3 and weight gain following smoking
cessation has also been associated with an increased
risk of smoking relapse.4
There is a general consensus that smoking cessation
does lead to some degree of weight gain. There is
substantial evidence from experimental studies indi-
cating that cigarette smoking exerts an appetite-
suppressant effect,5 and it has long been recognized
that cigarette smoking is employed as a means of
weight control, particularly by women,6 possibly
mediated via a lowering of the body weight set
point following chronic nicotine use.7 Epidemiological
evidence consistently shows that smokers have a
lower body mass index (BMI) than non-smokers,8,9
but whether smoking exposure is causal to lower
BMI is unclear.
Recently, a number of genome-wide association
(GWA) studies have provided robust evidence that
genetic variation at the CHRNA5-CHRNA3-CHRNB4
locus on chromosome 15q25 is associated with quan-
tity of smoking10–16 in those who smoke. Each add-
itional copy of the T-allele of the single-nucleotide
polymorphism (SNP), rs1051730, is associated with
an increase in smoking quantity of about one cigar-
ette per day.10 However, the similarity of allele fre-
quency between ever and never smokers does not
support association of this variant with smoking
initiation.10 The rs1051730 SNP lies within the nico-
tinic acetylcholine receptor-a 3 subunit gene
(CHRNA3), but is in linkage disequilibrium with a
large number of other SNPs across CHRNA3,
CHRNA5 and CHRNB4. The functional variant at the
15q25 locus is not known. The minor allele of the
mis-sense polymorphism, D398N (rs16969968), in
CHRNA5, conferred a reduced response to a nicotinic
agonist in vitro.17 However, a recent study, which used
data from the 1000 Genomes Project to impute virtu-
ally all common variants in the region, showed that
rs55853698, in the 50-untranslated region of CHRNA5,
was the most strongly associated SNP.14 Both
rs16969968 and rs55853698 are highly correlated
with rs1051730 in Europeans (all pairwise r240.96).14
The association between variation at the 15q25 locus
and BMI is not known. Since genotypes are (i) as-
signed at conception and (ii) not generally associated
with the wide range of environmental characteristics
that confound conventional epidemiological associ-
ation studies,18 genetic variation at 15q25 should
serve as an unconfounded measure of smoking expos-
ure in smokers, unbiased by reverse causality. If cig-
arette smoking is causally associated with lower BMI,
we would expect the allele that predisposes to heavier
smoking to be associated with a lower BMI in those
who smoke, but not in those who have never smoked.
This would constitute a gene environment inter-
action, and would provide strong evidence of caus-
ality.19 To investigate this, we performed a
meta-analysis (n¼ 24 198 participants; k¼ 9 study
samples) to examine the association between the
rs1051730 variant and BMI. We stratified our analyses
by smoking status, and tested for a geno-
type smoking status interaction.
Methods
Study participants
We analysed data on a total of 24 198 participants
from nine study samples. All participants gave in-
formed consent and ethical approval was obtained
from the relevant local review committees. In each
study, BMI was calculated as weight (kg) divided by
height squared (m2).
The Avon Longitudinal Study of Parents
and Children
This is a prospective study, which recruited pregnant
women from Bristol, UK, with expected delivery dates
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between April 1991 and December 1992. Ethical ap-
proval was obtained from the Avon Longitudinal
Study of Parents and Children (ALSPAC)20 Law and
Ethics Committee in addition to the local review com-
mittee. Data collection on smoking behaviour have
been described previously.21 Women were grouped
as never smokers, former smokers or current smokers
on the basis of a questionnaire administered in the
18th week of gestation. The latter two categories were
combined in analyses that compared strata of never
with ever smokers. Pre-pregnancy BMI was calculated
from self-reported pre-pregnancy weight and height.
We included a total of 6148 women of European an-
cestry, with rs1051730 genotype, BMI and smoking
data available.
The British Regional Heart Study
The study recruited 7735 men aged 40–59 years in
1978–80; full details are reported elsewhere.22 Men
were recruited from 24 medium-sized British towns;
at that time, very few eligible subjects were of non-
European ancestry. Twenty years later, when aged
60–79 years, n¼ 4252 participants were re-measured
and provided a whole-blood sample from which DNA
was extracted. The physical examination included
weight and height. Height without shoes and weight
in trousers and socks were measured, to the nearest
millimetre and 0.1 kg, respectively. Participants were
asked whether they had ever smoked cigarettes regu-
larly and, if yes, whether they smoked cigarettes now;
from these two questions, we defined current smo-
kers, former smokers and never smokers. Cotinine
was assayed by a widely applied gas chromatographic
method with a detection limit of 0.1 ng/ml.23 Regular
internal quality controls were run to ensure compar-
ability and reliability of results over time. For
non-smokers, cotinine levels were further defined
using a liquid chromatography tandem mass spec-
trometry (LC–MS/MS) assay with a lower limit of
detection of 0.02 ng/ml and with a limit of quantifi-
cation of 0.1 ng/ml. Cotinine values at the limit of
quantification (0.1 ng/ml) were assigned a value of
0.05 ng/ml. Further details of the assay can be ob-
tained from abslabs@biopark.org.uk. In the current
analyses, we included 3870 participants with
rs1051730 genotype, BMI and smoking data available.
The British Women’s Heart and Health Study
The study randomly selected and recruited 4286
women aged 60–79 years, from 23 British towns, be-
tween 1999 and 2001. The women were interviewed,
examined, completed medical questionnaires and had
detailed reviews of their medical records. Full selec-
tion and baseline measurement details of the study,
including measurement of height and weight (as-
sessed without shoes and in light clothing to the
nearest millimetre and 0.1 kg, respectively), have
been previously reported.24,25 Smoking history
(never, former and current, including the amount
and details of starting and quitting) were
self-reported at baseline, either at the research nurse
interview or in the mailed questionnaires. Serum
samples collected at baseline were assayed for coti-
nine levels in exactly the same way as in the British
Regional Heart Study (BRHS).23 After excluding par-
ticipants of known non-White ethnicity, or who had
missing rs1051730 genotype, smoking or BMI data,
there were 3634 women available for analysis.
The CoLaus Study
This is a population-based study of 6188 individuals,
aged 35–75 years, randomly selected from the list of
residents in Lausanne, Switzerland, between 2003 and
2006.26 Risk factors for cardiovascular diseases were
assessed and DNA and plasma samples were collected
for the study of genetic variants and biomarkers.
Between 2004 and 2008, all 35- to 66-year-old indi-
viduals of the CoLaus sample were invited to partici-
pate in a psychiatric sub-study (PsyCoLaus).27
Detailed descriptions of recruitment procedures and
assessments have been provided previously.26,27 The
physical assessment within the CoLaus study included
measurement of body weight and height, from which
BMI was calculated. Ever smokers were those who
had smoked regularly at some point in their life. Of
these, individuals who smoked at least one cigarette
daily at the time of interview were classified as cur-
rent smokers, whereas the rest were classified as
former smokers. For the purpose of genetic analysis,
only individuals with European origin were included
(n¼ 5692), and of these, a total of 5426 participants
had the genotype and phenotype data necessary for
inclusion in the current study.
The Exeter Family Study of Childhood Health
This is a prospective study of children born between
2000 and 2004, and their parents, from a geographic-
ally defined region of Exeter, UK.28 Data collection on
smoking behaviour have been described previously.21
In the current study, we included 811 pregnant
women and 762 men of European ancestry. We
grouped them as never, former or current smokers
on the basis of questionnaire data collected during
the 28th week of gestation. Height and weight were
measured at that time by research midwives and used
to calculate BMI. Since women were pregnant at the
time of data collection, we analysed men and women
separately in the current study. For the women-only
analysis, we used pre-pregnancy BMI (calculated from
self-reported pre-pregnancy weight).
The Danish GOYA Male Study
Among 362 200 Caucasian men examined at the mean
age of 20 years at the draft boards in Copenhagen and
its surroundings during 1943–77, a randomly selected
control group of 1 in every 100 men (n¼ 3601) and all
obese men (n¼ 1930) were manually identified.
CHROMOSOME 15Q25 VARIANT, SMOKING AND BMI 1619
Obesity was defined as 35% overweight relative to a
local standard in use at the time, and this corresponds
to a BMI5 31.0 kg/m2, which proved to be above the
99th percentile. All obese men and half of the random
sample, still living in the region, were invited to a
follow-up survey in 1992–94 at the mean age of
46 years. The criteria for invitation to the follow-up
surveys and the participation have been described pre-
viously.29–31 A total of 1441 men (661 obese and 780
randomly selected) were included in the present study
with BMI, smoking status and rs1051730 genotype
data available.
The MIDSPAN Family Study
This is one of the four MIDSPAN population cohort
studies based in Scotland.32 The three original studies
took place between 1964 and 1976. Twenty years
later, in 1996, the next generation was studied
when offspring of couples in the original Renfrew/
Paisley Study were recruited into the Family Study.
This latter group is the subject of the present analysis.
The offspring were ascertained (by self-report) to be
from full-sibling families with no step children,
adoptees or half-siblings. All were White and living
in the west of Scotland. Details of the study have
been described previously.33 Standing height was
measured without shoes. A single measurement (to
the nearest 1 mm) was made after participants
inhaled and stretched to reach their maximum
height. Weight was measured to the nearest 0.1 kg
without shoes and wearing indoor clothes. Data on
smoking habit (never, current or former) were col-
lected via questionnaires completed by the partici-
pants. Serum samples were assayed for cotinine at
ABS Laboratories Ltd, London, UK. For smokers and
non-smokers, capillary column gas–liquid chromatog-
raphy with a nitrogen detector was used. The lower
limit of detection was 0.1 ng/ml.23 In the current ana-
lyses, we included 2106 individuals of European an-
cestry with rs1051730 genotype, BMI and smoking
data available.
Genotyping
The genotyping of the rs1051730 variant in the
ALSPAC and The Exeter Family Study of Childhood
Health (EFSOCH) studies has been described previ-
ously.21 In the British Women’s Heart and Health
Study (BWHHS) and BRHS studies, genotyping of
rs1051730 was performed by KBioscience (http://
www.kbioscience.co.uk), using KASPar chemistry,
which is a competitive allele-specific PCR SNP geno-
typing system. The respective genotyping call rates
were 98.2 and 98.7%, and there was no evidence of
deviation from Hardy–Weinberg Equilibrium (HWE;
BWHHS P¼ 0.58; BRHS P¼ 0.29). In the BWHHS,
blind duplicates (concordance 100%) were used
as additional quality control tests. In the MIDSPAN
study, genotyping was performed on an ABI PRISM
7900HT sequence detection system using a Taqman
assay (Assay ID: C_9510307_20, Applied Biosystems),
followed by allelic discrimination using software from
Applied Biosystems (SDS V2.0).34,35 All genotyping
errors were manually resolved by checking raw geno-
type data, individuals were either blanked (zeroed) or
corrected prior to analysis. The call rate was 94.5%
and there was no evidence of deviation from HWE
(P¼ 0.92), which was assessed using the eldest sib-
ling from each family to ensure a sample of unrelated
individuals (n¼ 1386).
In the CoLaus study, genome-wide SNP genotyping
was performed using the Affymetrix 500 K SNP chip.
Samples were excluded if they showed gender incon-
sistencies or had an efficiency <90%. Marker quality
control resulted in exclusion of SNPs that were mono-
morphic (4052), had a call rate <95% (30 873),
deviated (P< 103) from HWE (35 417) or had
minor allele frequencies <0.01 (61 654), leaving a
total number of 370 162 genotyped markers for ana-
lysis. Imputation of SNP genotypes was performed
using the software IMPUTE v.0.5.036 based on the
HapMap CEU II samples. Approximately 2.5 million
markers were imputed. A total of 89 SNPs (34 geno-
typed and 55 imputed) within the CHRNA5-
CHRNA3-CHRNB4 gene region were obtained. The
SNP rs1051730 was imputed in the study sample
with a posterior call rate of 0.97.
In the GOYA study, genome-wide SNP genotyping
was performed using the Illumina 610 K Quad SNP
chip. The rs1051730 SNP was genotyped on this plat-
form. Individuals were excluded if they showed
gender inconsistencies, if they had a genotyping suc-
cess rate of <95%, if they had outlying heterozygosity
(<0.30 or40.35) or if they clustered with individuals
of non-European ancestry on multi-dimensional scal-
ing analysis. We also excluded one individual from
each pair that appeared to be related (identity by
descent40.2). The rs1051730 SNP had an overall
call rate of 99.9% and the Hardy–Weinberg P-values
were 0.21 and 0.44 in the controls and obese cases,
respectively.
Statistical methods
Within-study analyses
Within each study, we verified that the association
between smoking quantity and rs1051730 genotype
was consistent in magnitude and direction with pub-
lished data (data not shown, but the association has
been previously published for the ALSPAC, CoLaus
and EFSOCH women studies14,21). We then stratified
by smoking status in each study (for our main ana-
lyses into never and ever strata, and for our second
analyses into finer strata of never, former and cur-
rent). To test for association between BMI and
rs1051730 genotype within each stratum, we per-
formed linear regression of log-transformed BMI
against genotype (coded as 0, 1 or 2 T-alleles; additive
genetic model). We repeated the analysis including
age and sex (where appropriate) as covariables. We
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then analysed the association between BMI and geno-
type, adjusting for smoking quantity (cigarettes per
day) where available, in the current and former
smoker strata. In addition, we analysed the associ-
ation between BMI and genotype, adjusting for mea-
sured cotinine levels (available in the BRHS, BWHHS
and MIDSPAN studies only). In the MIDSPAN study,
which includes related individuals, associations be-
tween BMI and SNP genotype were investigated
using linear mixed effects regression models fitted
using restricted maximum likelihood (REML).
Family structure among the MIDSPAN offspring gen-
eration was accounted for by fitting random inter-
cepts within sibships.
Meta-analysis
Meta-analysis statistics and plots were produced
using the inverse-variance method (fixed effects), im-
plemented in the ‘metan’ module developed for Stata
(StataCorp, College Station, TX, USA).37 We pooled
regression coefficients and standard errors from the
linear regression analyses performed in the individual
studies. We used the I2 statistic to estimate the per-
centage of total variation in study estimates that is
because of between-study heterogeneity38 and derived
95% confidence intervals (95% CIs) for I2 using the
user-written Stata command, ‘heterogi’. Convention-
ally, I2 values of 25, 50 and 75% represent low, mod-
erate and high heterogeneity, respectively. In addition,
we used Cochran’s Q-test to evaluate the statistical
evidence for between-study heterogeneity, both
within and between the strata defined by smoking
status. The test of heterogeneity between strata
served as a test of interaction between genotype and
smoking status. As a sensitivity analysis, we repeated
the meta-analysis excluding the ALSPAC and
EFSOCH women studies, which analysed pre-
pregnancy BMI, but which stratified by smoking
status (never/former/current) using data collected
during pregnancy.
Estimation of approximate overall effect sizes in
kilogram per square metre
Since the outcome was natural log transformed, we
obtained the percentage change in the average value
of BMI per allele using 100 x [exp(beta)–1], where
‘beta’ is the effect size on the logBMI scale. We
took the median study BMI within each stratum
(never/former/current/ever) as the average value.
Results
The basic characteristics of study participants are pre-
sented in Table 1. The associations between BMI and
the rs1051730 variant are presented (overall and by
study) in Figure 1 and Tables 2 and 3. In the ever
smokers, each additional T-allele, which is associated
with greater smoking quantity, was associated with
a 0.9% (95% CI: 0.5–1.2) lower BMI (P¼ 8 106).
This equates to a difference of 0.23 kg/m2 (95% CI:
0.13–0.31), relative to the median study BMI for
ever smokers (25.8 kg/m2). However, in the never
smokers, we observed no evidence of association be-
tween BMI and the genotype [0.2% BMI change
(0.2 to 0.7)], which equates to 0.05 kg/m2 (95% CI:
0.05 to 0.18) per T-allele (median study BMI for
never smokers¼ 25.5 kg/m2; P¼ 0.25). There was low
heterogeneity within each of the two strata [I2¼ 21%
(95% CI: 0–62), P¼ 0.26 for never; I2¼ 0% (95% CI:
0–65), P¼ 0.91 for ever smokers], but strong evidence
of heterogeneity between the strata (P¼ 0.0001), indi-
cating an interaction between genotype and smoking
status in their association with BMI.
When dividing the ever-smoker group into current
and former smokers, we observed evidence of associ-
ation in both strata (Figure 1b and Table 3), but with
a larger effect size in current smokers. In the former
and current smokers, respectively, there was a 0.6%
(95% CI: 0.1–1.1) and 1.3% (95% CI: 0.7–1.9) lower
BMI per T-allele. These effect sizes equate, respect-
ively, to differences of 0.16 kg/m2 (95% CI: 0.03–
0.29) and 0.33 kg/m2 (95% CI: 0.18–0.48), relative to
the median study BMIs in these groups (26.3 kg/m2
former and 25.6 kg/m2 current). There was no detect-
able heterogeneity within these strata [I2¼ 0%
(95% CI: 0–65), P¼ 0.97 for former; I2¼ 0% (95%
CI: 0–65), P¼ 0.55 for current smokers], but strong
evidence of heterogeneity among the never, former
and current smoker strata (P¼ 0.0002).
Overall, across all smoking status strata, each add-
itional T-allele was associated with a 0.4% (95% CI:
0.1–0.7) lower BMI (P¼ 0.007; Figure 1), which
equates to a difference of 0.10 kg/m2 (95% CI: 0.03–
0.18) (median overall study BMI¼ 25.8 kg/m2).
The results were not materially altered on adjust-
ment for age and sex (Tables 2 and 3). A sensitivity
analysis excluding the ALSPAC and EFSOCH preg-
nant women produced very similar effect size esti-
mates (Tables 2 and 3).
Adjustment for smoking quantity, where available,
in the current and former smokers also did not sub-
stantially change the results (Table 3). Measured coti-
nine levels were available in the current smokers of
the BRHS, BWHHS and MIDSPAN studies.
Adjustment for cotinine levels resulted in attenuation
of the association between genotype and BMI [1.0%
(95% CI: –0.3 to 2.3)] lower per T-allele (P¼ 0.13),
relative to the association adjusted for reported smok-
ing quantity in BRHS, BWHHS and MIDSPAN only:
2.0% lower BMI (95% CI: 0.6–3.2, P¼ 0.005; Table 3).
Discussion
In a meta-analysis of 24 198 individuals from nine
study samples, we have shown that there is an inter-
action between smoking status and genotype of the
15q25 variant, rs1051730, in relation to BMI. In never
smokers, we observed no evidence of association
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Table 1 Basic characteristics of study participants
Study Sample group Participants, na (% male) Age, median (IQR) BMI, median (IQR)
ALSPACb Never smokers 3193 (0) 29 (26–32) 22.2 (20.5–24.4)
Former smokers 1851 (0) 29 (25–32) 22.4 (20.7–24.8)
Current smokers 1104 (0) 26 (24–30) 22.0 (20.3–24.7)
Ever smokers 2955 (0) 28 (25–31) 22.3 (20.5–24.8)
All 6148 (0) 28 (25–32) 22.2 (20.6–24.5)
BRHS Never smokers 1124 (100) 67 (64–72) 26.3 (24.3–28.5)
Former smokers 2243 (100) 69 (65–74) 26.9 (24.9–29.4)
Current smokers 503 (100) 68 (64–72) 25.9 (23.4–28.1)
Ever smokers 2746 (100) 69 (64–74) 26.7 (24.6–29.2)
All 3870 (100) 68 (64–73) 26.6 (24.5–29.0)
BWHHS Never smokers 2047 (0) 69 (64–73) 27.0 (24.0–30.0)
Former smokers 1194 (0) 69 (64–74) 27.0 (25.0–31.0)
Current smokers 393 (0) 67 (63–72) 26.0 (23.0–29.0)
Ever smokers 1587 (0) 69 (64–73) 27.0 (24.0–30.0)
All 3634 (0) 69 (64–73) 27.0 (24.0–30.0)
CoLaus Never smokers 2193 (38.0) 53 (44–62) 25.3 (22.6–28.3)
Former smokers 1801 (54.9) 56 (47–63) 25.8 (23.1–28.8)
Current smokers 1432 (51.2) 50 (43–60) 24.7 (22.1–27.7)
Ever smokers 3233 (53.3) 53 (45–62) 25.3 (22.6–28.3)
All 5426 (47.1) 53 (44–62) 25.3 (22.6–28.3)
EFSOCH MEN Never smokers 376 (100) 32 (30–36) 26.6 (24.6–28.7)
Former smokers 181 (100) 33 (30–37) 26.5 (24.5–29.2)
Current smokers 205 (100) 32 (27–25) 26.2 (23.2–29.2)
Ever smokers 386 (100) 32 (29–36) 26.4 (24.0–29.2)
All 762 (100) 32 (29–36) 26.5 (24.2–29.0)
EFSOCH_WOMENb Never smokers 593 (0) 31 (29–34) 22.9 (21.1–25.3)
Former smokers 118 (0) 29 (25–32) 23.4 (21.0–25.5)
Current smokers 100 (0) 29 (24–32) 23.7 (20.9–27.7)
Ever smokers 218 (0) 29 (25–32) 23.5 (20.9–26.6)
All 811 (0) 31 (27–34) 23.0 (21.1–25.5)
GOYA MEN CONTROLS Never smokers 174 (100) 44 (40–49) 25.4 (23.5–28.7)
Former smokers 216 (100) 48 (42–54) 26.2 (24.2–28.4)
Current smokers 390 (100) 47 (42–55) 25.6 (23.6–27.8)
Ever smokers 606 (100) 47 (42–55) 25.8 (23.7–28.1)
All 780 (100) 46 (41–53) 25.8 (23.6–28.2)
GOYA MEN OBESE Never smokers 163 (100) 41 (37–45) 35.8 (32.2–39.9)
Former smokers 148 (100) 43 (40–48) 35.2 (32.7–40.3)
Current smokers 350 (100) 42 (38–47) 34.5 (31.6–38.2)
Ever smokers 498 (100) 42 (39–47) 34.6 (31.8–38.6)
All 661 (100) 42 (38–46) 34.9 (32.0–39.1)
MIDSPAN Never smokers 996 (43.0) 45 (40–49) 25.5 (23.1–28.4)
Former smokers 574 (49.7) 47 (42–50) 26.3 (24.0–29.2)
Current smokers 536 (44.2) 46 (40–50) 24.6 (22.1–28.1)
Ever smokers 1110 (47.0) 46 (41–50) 25.6 (23.0–28.8)
All 2106 (45.1) 45 (41–49) 25.5 (23.0–28.6)
Ever smokers: former plus current. IQR: inter-quartile range.
aN included in main analysis.
bPre-pregnancy BMI was analysed in ALSPAC and EFSOCH_WOMEN.
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between rs1051730 genotype and BMI. However, in
ever smokers, there was strong evidence that each
additional copy of the T-allele, which is associated
with higher smoking quantity, was associated with a
0.23 kg/m2 (95% CI: 0.13–0.31) lower BMI (inter-
action P¼ 0.0001). The association in the ever smo-
kers was consistent across studies (heterogeneity
P¼ 0.91), despite variation in mean BMI because of
age and ascertainment differences.
Our results support the hypothesis that exposure to
cigarette smoking is causally associated with lower
BMI. Genotype–phenotype associations are not
biased by reverse causality, and genotypes are gener-
ally randomized to factors that usually confound epi-
demiological studies.18 We have shown previously
that the rs1051730 variant, which is robustly asso-
ciated with smoking quantity,10–16 is not associated
with covariates of smoking behaviour including age,
education level and occupational position.21 We can,
therefore, be confident that the association we have
observed between rs1051730 genotype and BMI in
ever smokers, together with the null association in
never smokers, reflects a causal relationship between
smoking exposure and lower BMI. Our data add sup-
port to evidence from previous epidemiological, ex-
perimental and physiological studies.5–7,9,39
Subdivision of the ever-smoker group showed that
the effect size was smaller in former smokers
[0.16 kg/m2 (95% CI: 0.03–0.29) lower BMI per
T-allele] than in current smokers [0.33 kg/m2 (95%
CI: 0.18–0.48) lower BMI per T-allele]. This suggests
that the association with BMI weakens over time
after cessation. It is consistent with the observation
that cigarette smokers who attempt to quit experience
a short-term rebound effect, whereby a marked initial
weight gain following smoking cessation is a result of
the removal of the lowered body weight set point
induced by chronic nicotine use,7 and reduced sym-
pathovagal ratio and resensitization of nicotinic recep-
tors.39 Smoking cessation is associated with a
corresponding average increase in BMI,9 and compari-
sons of BMI over time suggest that when cigarette
smokers achieve long-term abstinence from tobacco
they revert to a mean BMI roughly equivalent to
that of never smokers. Weight gain on cessation of
smoking is associated with increased risk of relapse
into smoking.4 Taken together, these observations
suggest that smoking cessation initiatives may be
more successful if accompanied by support to main-
tain a healthy BMI.
We did not observe attenuation of the associations
between genotype and BMI upon adjustment for
Figure 1 Meta-analysis plots of the association between the rs1051730 variant and BMI, stratified by smoking status.
(a) Never/ever smokers. There was strong evidence of heterogeneity between strata (P¼ 0.0001). In the ever smokers, the
effect size equates to a 0.23 kg/m2 (95% CI: 0.130.31) lower BMI per T-allele. In the never smokers, there was no evidence
of association [BMI difference per T-allele: 0.05 kg/m2 (95% CI: 0.05 to 0.18)]. (b) Never/former/current smokers. There
was strong evidence of heterogeneity among the three strata (P¼ 0.0002). In the former and current smokers, there was a
0.16 kg/m2 (95% CI: 0.03–0.29) and 0.33 kg/m2 (95% CI: 0.18–0.48) lower BMI per T-allele, respectively. Overall, across all
smoking status strata, each additional T-allele was associated with a 0.10 kg/m2 (95% CI: 0.03–0.18) lower BMI
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smoking quantity in the former and current smokers.
We would expect these associations to get weaker if,
as we hypothesize, the genotype–BMI association is
mediated by smoking quantity. However, since data
on smoking quantity were self-reported, they were
unlikely to have captured the exposure fully.
Moreover, adjustment for cotinine levels in the avail-
able samples did result in attenuation, and our obser-
vation that there was no association between
genotype and BMI in the never smokers is consistent
with the associations observed being mediated by
smoking. The observation that the effect of the
rs1051730 variant on BMI is robust to adjustment
for smoking quantity suggests that, even within
heaviness of smoking strata, the rs1051730 variant
exerts an influence on exposure, possibly via individ-
ual differences in smoking topography (e.g. depth of
puff inhalation, number of puffs). This further sup-
ports a causal association between exposure and BMI,
both between and within heaviness of smoking strata,
and suggests that simple measures of heaviness of
smoking based on reported quantity may mask im-
portant inter-individual variation in behaviour and
subsequent exposure.
Although the association between rs1051730 geno-
type and smoking quantity has mostly been described
in Europeans, it has also been observed in populations
of African–American and Korean descent.40–42 Further
work is needed to investigate the relationships be-
tween genotype, smoking and BMI in non-European
populations.
We acknowledge some limitations to our study.
First, in the ALSPAC and EFSOCH studies, pre-
pregnancy BMI was analysed, whereas smoking data
were collected during pregnancy. Therefore, the tem-
poral distinction between former and current smokers
may have been different from that in the other stu-
dies. However, a sensitivity analysis excluding these
studies produced very similar effect size estimates of
the associations within each smoking status stratum.
Secondly, different methods and instruments were
used for assessing weight and height, as well as
smoking in the studies that were pooled here.
However, we found little evidence for marked hetero-
geneity between studies within strata. Thirdly, our
statistical evidence for association with BMI in
the ever smokers (P¼ 8 106), and for the geno-
type smoking status interaction (P¼ 0.0001), al-
though strong, is modest in relation to levels now
necessary for robust candidate gene association stu-
dies. However, the fact that the 15q25 variant is now
incontrovertibly associated with smoking quantity
greatly increases the prior odds of association.
To conclude, the 15q25 smoking quantity variant is
associated with a lower BMI in former and current
smokers, but not in individuals who have never
smoked. This is a clear example of a gene environ-
ment interaction because the association between
genotype and BMI is dependent upon smoking
status. Our observations support the hypothesis that
smoking is causally associated with reduced BMI.
Smoking cessation initiatives might be more success-
ful if they include support to maintain a healthy BMI
at the same time as quitting smoking.
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KEY MESSAGES
 A genetic variant on chromosome 15 is known to be associated with a higher smoking quantity in
smokers. We show that the higher smoking quantity genotypes are also associated with a lower BMI
in current and former smokers.
 There is no association between genotype and BMI in never smokers.
 Since genotype is assigned at conception and reflects smoking exposure in smokers, our results
strengthen evidence that smoking is causally related to lower BMI.
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